Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Kadokura T, Akiyama N, Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Nagase I, Smulders R, Kageyama S. Kadokura T, et al. Among authors: akiyama n. Diabetes Res Clin Pract. 2014 Oct;106(1):50-6. doi: 10.1016/j.diabres.2014.07.020. Epub 2014 Jul 26. Diabetes Res Clin Pract. 2014. PMID: 25149596 Clinical Trial.
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A, Sakatani T, Nakamura I, Akiyama N, Kazuta K, Ueyama E, Takahashi H, Kosakai Y. Kashiwagi A, et al. Among authors: akiyama n. Endocr J. 2018 Jul 28;65(7):693-705. doi: 10.1507/endocrj.EJ17-0491. Epub 2018 May 29. Endocr J. 2018. PMID: 29848902 Free article. Clinical Trial.
Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
Kashiwagi A, Yoshida S, Kawamuki K, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Akiyama N, Kondo Y, Ogihara T. Kashiwagi A, et al. Among authors: akiyama n. Diabetol Int. 2016 Sep 9;8(1):76-86. doi: 10.1007/s13340-016-0283-x. eCollection 2017 Mar. Diabetol Int. 2016. PMID: 30603310 Free PMC article.
Importance of EQA/PT for the detection of genetic variants in comprehensive cancer genome testing.
Matsushita K, Ishige T, Watanabe K, Akahane T, Tanimoto A, Yoshimoto M, Yamakuchi M, Hashiguchi T, Okugawa Y, Ikejiri M, Yamaguchi T, Yamasaki T, Takeda M, Hibi M, Akiyama N, Shimizu K, Hashimoto N, Sato H, Tanaka Y, Amari F; EQA working group of Japan Association for Clinical Laboratory Science(JACLS). Matsushita K, et al. Among authors: akiyama n. Sci Rep. 2025 Jan 7;15(1):1036. doi: 10.1038/s41598-024-84714-4. Sci Rep. 2025. PMID: 39762492 Free PMC article.
Immune checkpoint inhibitor-induced autoimmune limbic encephalitis with positivity for anti-Hu antibodies in a patient with small-cell lung cancer: A case report and literature review.
Nakahara L, Matsuura S, Suzuki R, Kawamura A, Nagasaki T, Masuda T, Yamada K, Nakamura R, Hiramatsu T, Akiyama N, Tanaka K, Koshimizu N, Igasaki S. Nakahara L, et al. Among authors: akiyama n. Respirol Case Rep. 2024 Nov 25;12(11):e70070. doi: 10.1002/rcr2.70070. eCollection 2024 Nov. Respirol Case Rep. 2024. PMID: 39588329 Free PMC article.
438 results